Instituto Alexander Fleming
Argentina's leading private cancer institute, a key site for international breast, lung and gastrointestinal trials and the home of the Argentine cooperative group tradition.
The Instituto Alexander Fleming was founded in Buenos Aires in 1994 as a dedicated cancer institute by a group of oncologists including Reinaldo Chacón, and has become Argentina's most research-active cancer centre, with medical, surgical and radiation oncology, haematology, nuclear medicine and a large clinical research department that has enrolled Argentine patients in many of the pivotal breast (HER2, CDK4/6), lung and colorectal cancer trials of the last three decades. It hosts the Grupo Argentino de Investigación Clínica en Oncología (GAICO) and links with the Latin American Cooperative Oncology Group, offers a fellowship programme and tumour banking, and was an early adopter in Argentina of precision oncology and next-generation sequencing.
- International clinical trials
- Breast and lung oncology
- Cooperative group (GAICO)
- Precision oncology
Pages like this
not linked directly; found by shared links- PersonDennis J. Slamon
Shares Palbociclib, CDK4/6, Trastuzumab, HER2.
- PersonYeon Hee Park
Shares Palbociclib, CDK4/6, HER2, HER2-positive breast cancer.
- TrialPALOMA-2
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- PersonAngela DeMichele
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- TrialPALLAS & PENELOPE-B
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- InstitutionHospital del Mar / Hospital del Mar Research Institute
Shares Trastuzumab, HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- TrialINAVO120
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- InstitutionAichi Cancer Center
Shares Comprehensive genomic profiling, HR-positive / HER2-negative breast cancer, Colorectal cancer, Non-small-cell lung cancer.